摘要
本文首先介绍高血脂症,高血脂症是由于血脂代谢异常引发的,血脂成分主要有胆固醇、甘油三酯、磷脂及游离脂肪酸,其代谢异常主要为总胆固醇(TC)或甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、极低密度脂蛋白(VLDL)异常或出现乳糜微粒。阿昔莫司可通过降低血浆中甘油三脂的含量,提高血浆中高密度脂蛋白含量,还可以和他汀类降脂药物联合使用治疗混合型高血脂症,提高血浆中高密度脂蛋白含量,可降低低密度脂蛋白在血浆中含量,从对高血脂症的病原出发,降血脂药物的类型和作用机理分别为以降低胆固醇为主的药物含不饱和脂肪酸的药物;以降低低密度脂蛋白胆固醇为主的他汀类药物;既降胆固醇又降甘油三酯的贝特类药物;烟酸类及其衍生物,最后从国内制药企业专利的角度分析药物阿昔莫司的专利现状及前景。
This article first introduced the hyperlipemia,hyperglycemia,dyslipidemia is due to the blood cholesterol,triglyceride,phospholip ids and free fatty acids,the main metabolic abnormalities as total cholesterol（TC）and triglyceride（TG）,low density lipoprotein（LDL）,high- density lipoprotein（HDL）,low density lipoprotein（VLDL）abnormal or chyle particles.Low a body lipid metabolic abnormalities,acyclovir therapy can decrease the plasma levels of triglycerides in the raise HDL levels in plasma,and can also be used in combination with statins lipid-lowering drugs to treat mixed hyperlipidemia,raise HDL levels in plasma,can reduce low-density lipoprotein（LDL）levels in the blood plasma,starting from the pathogen of hyperlipidemia,fall hematic fat,the types and mechanisms of drug,respectively is given priority to with lower cholesterol drugs containing unsaturated fatty acid; Statin drugs that reduce LDL cholesterol; Bette drugs that reduce cholesterol and triglycerides; Nicotinic acid and its derivatives,finally,from the perspective of domestic pharmaceutical enterprise patent,analysis of the patent situation and prospects of the drug.
出处
《化工管理》
2018年第7期5-7,共3页
Chemical Engineering Management
